| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||||||
-120,551 | -96,967 | -88,205 | -73,740 | -29,102 | -36,140 | -66,083 | -19,712 | -15,304 | -17,638 | -24,458 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation | ||||||||||
3,598 | 3,747 | 1,850 | 1,708 | 1,048 | 626 | 328 | 173 | 142 | 194 | 237 |
Amortization of Intangible Assets | ||||||||||
1,066 | 1,249 | 1,618 | 1,377 | 870 | 942 | 1,770 | 1,821 | 1,869 | 1,913 | 1,439 |
Amortization of operating lease right-of-use assets | ||||||||||
851 | - | - | - | - | - | - | - | - | - | - |
Change in fair value of common stock warrants | ||||||||||
0 | -360 | -806 | -127 | -177 | -348 | 45,632 | -1,982 | -8,690 | -2,403 | 1,286 |
Change in fair value of derivative liability | ||||||||||
1,763 | 0 | 0 | - | - | - | - | - | - | - | - |
Change in value of short-term investmentsauction rate securities | ||||||||||
- | - | - | - | - | - | - | - | - | -3,152 | - |
Change in value of auction rate security rights | ||||||||||
- | - | - | - | - | - | - | - | - | 3,145 | -1,228 |
Gain on long-term investments | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,136 |
Stock-based compensation | ||||||||||
10,901 | 10,654 | 13,070 | 10,479 | 6,186 | 5,428 | 1,868 | 1,345 | 1,654 | 1,174 | 2,157 |
Non-cash interest expense | ||||||||||
5,230 | 0 | 0 | - | - | - | - | - | - | - | - |
Interest converted into common stock | ||||||||||
- | - | - | - | - | - | - | - | - | - | 430 |
Issuance of shares in connection with reverse stock split | ||||||||||
- | - | - | - | - | -57 | 0 | 0 | - | -61 | -166 |
Amortization of premiums on investments | ||||||||||
1 | 72 | 319 | 266 | 348 | 54 | -0 | 0 | - | - | - |
Deferred taxes | ||||||||||
-5 | 0 | 150 | 0 | -14 | - | - | - | - | - | - |
Transaction costs associated with issuance of warrants | ||||||||||
- | - | - | - | - | - | 315 | 0 | 0 | - | - |
Loss on short-term investments | ||||||||||
- | - | - | 139 | 432 | 36 | 38 | 0 | 0 | 25 | - |
Reserve for inventory purchased from related parties | ||||||||||
- | - | - | - | - | - | - | - | - | - | 177 |
Deferred taxes | ||||||||||
- | - | - | - | - | 27 | 32 | 22 | 25 | -53 | 887 |
Amortization of premiums on investments | ||||||||||
- | - | - | - | - | - | - | -1 | 6 | -6 | - |
Loss on short-term investments | ||||||||||
476 | -1,342 | -215 | - | - | - | - | - | - | - | - |
Loss on disposal of fixed assets | ||||||||||
-5 | -14 | 0 | 0 | - | - | -1 | 0 | 0 | -21 | -26 |
Deferred rent | ||||||||||
- | - | - | - | - | - | - | - | - | - | 131 |
Change in Value of Investments in Affiliated Company | ||||||||||
-3,090 | -1,988 | -6,982 | 1,110 | 2,600 | 2,676 | -1,038 | 1,631 | -2,390 | -969 | -9,244 |
Transaction costs associated with issuance of warrants | ||||||||||
- | - | - | - | - | - | - | - | 0 | - | - |
Gain on sale of intangible assets | ||||||||||
0 | 0 | 1,000 | 1,000 | 1,000 | 0 | 2,000 | 1,151 | 587 | 0 | - |
Income tax benefit from other unrealized gains on securities | ||||||||||
- | - | - | - | 2,097 | 0 | 0 | - | - | - | - |
Tax benefit from other unrealized gains on short-term investments | ||||||||||
-266 | 0 | 0 | - | - | - | - | - | - | - | - |
Unrealized transaction loss on foreign-currency denominated debt | ||||||||||
471 | 0 | 0 | - | - | - | - | - | - | - | - |
Changes in operating assets and liabilities: | ||||||||||
Gain from long-term investment in affiliated entity | ||||||||||
- | - | - | - | - | - | - | - | - | - | 5 |
Accounts receivable | ||||||||||
-2,616 | -2,686 | -9,818 | 8,521 | 4,497 | -499 | 2,434 | 362 | 435 | -226 | -288 |
Accounts receivable from affiliated entities | ||||||||||
593 | 251 | -261 | 714 | 31 | 1 | - | -2 | -33 | 13 | -1,103 |
Prepaid expenses and other current assets | ||||||||||
178 | -1,194 | 851 | 831 | 119 | 160 | 229 | -363 | 472 | -35 | -242 |
Prepaid expenses and other current assets from affiliated entities | ||||||||||
-70 | -725 | 333 | 901 | -771 | -674 | 1,401 | 445 | -212 | 553 | - |
Restricted cash | ||||||||||
- | - | - | - | - | -100 | 0 | 0 | 100 | 0 | - |
Other assets | ||||||||||
2 | 30 | 526 | 1,442 | 196 | 72 | -26 | 14 | -50 | -21 | 18 |
Accounts payable and accrued expenses | ||||||||||
-4,337 | 550 | 2,829 | 6,367 | 6,456 | 925 | 2,123 | -790 | 1,789 | -156 | -1,043 |
Accrued clinical trial expenses | ||||||||||
-1,622 | -2,940 | 2,243 | - | - | - | - | - | - | - | - |
Accrued clinical trial expenses | ||||||||||
- | - | - | 3,767 | 593 | 561 | 40 | - | - | - | - |
Accounts payable and accrued expenses due to affiliated entities | ||||||||||
-248 | 50 | -145 | 907 | 136 | -493 | 334 | 166 | -1,660 | 1,235 | 428 |
Deferred revenue | ||||||||||
-180 | -1,016 | -13,689 | 1,527 | - | - | - | - | - | - | - |
Deferred revenue | ||||||||||
- | - | - | - | 10,191 | -260 | 3,179 | 282 | -333 | 140 | -4,673 |
Deferred revenue from affiliated entities | ||||||||||
-1 | -140 | -319 | -687 | -49 | -368 | -375 | -375 | -361 | 2,711 | - |
Deferred rent | ||||||||||
0 | 398 | -3,608 | 16 | -383 | -762 | -410 | 15 | -13 | -55 | - |
Operating lease right-of-use assets and liabilities, net | ||||||||||
-1,733 | - | - | - | - | - | - | - | - | - | - |
Grant funding liability | ||||||||||
1,899 | 4,165 | 0 | 0 | - | - | - | - | - | - | - |
Grant funding liability from affiliated entities | ||||||||||
816 | 27 | 0 | 0 | - | - | - | - | - | - | - |
Other liabilities | ||||||||||
-48 | 87 | 0 | 0 | - | - | - | - | - | - | - |
Net cash used in operating activities | ||||||||||
-97,850 | -73,550 | -63,208 | -62,555 | -12,438 | -29,823 | -15,381 | -22,306 | -19,755 | -11,937 | -14,080 |
Cash flows from investing activities: | ||||||||||
Purchases of investments | ||||||||||
100,950 | 88,155 | 95,700 | 57,317 | 63,526 | 47,185 | 15,399 | 9,142 | 18,193 | 8,000 | - |
Proceeds from sale or maturity of investments | ||||||||||
92,893 | 132,659 | 77,162 | 76,528 | 10,484 | 12,753 | 4,339 | 14,008 | 7,206 | 6,160 | - |
Sales of investments-auction rate securities | ||||||||||
- | - | - | - | - | - | - | - | - | 13,550 | - |
Purchases of capital assets | ||||||||||
987 | 2,085 | 10,293 | 2,738 | 2,781 | 1,379 | 176 | 240 | 161 | 181 | 48 |
Sale of capital assets | ||||||||||
- | - | - | - | - | - | - | - | - | 32 | - |
Additional investment in affiliated entity | ||||||||||
- | - | - | - | - | - | - | - | 101 | 0 | - |
Proceeds from sale of intangible assets | ||||||||||
0 | 0 | 1,000 | 1,000 | 1,000 | 0 | 2,000 | 650 | 350 | 0 | - |
Purchase of intangible and other assets | ||||||||||
- | - | - | 1,200 | 0 | 0 | - | - | - | 124 | 116 |
Net cash provided by acquisition | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,611 |
Net cash used in investing activities | ||||||||||
-9,044 | 42,419 | -27,831 | 16,271 | -54,824 | -35,812 | -9,236 | 5,275 | -10,899 | 11,435 | 1,446 |
Cash flows from financing activities: | ||||||||||
Proceeds from issuance of convertible senior notes | ||||||||||
97,443 | 0 | 0 | - | - | - | - | - | - | - | - |
Costs related to issuances of convertible senior notes and convertible bonds | ||||||||||
3,314 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from issuance of common stock, net of issuance costs | ||||||||||
9,089 | 29,227 | 94,347 | 6,295 | 81,902 | 59,209 | 32,883 | 5,325 | 27,994 | 2,314 | 28,406 |
Expenses from other financing activities | ||||||||||
- | - | - | -149 | -149 | 0 | 0 | - | - | - | - |
Proceeds from stock option exercises | ||||||||||
- | - | - | - | - | - | - | - | - | 168 | 358 |
Proceeds from stock option and warrant exercises, net of tax payments | ||||||||||
0 | 1,809 | 1,342 | 1,640 | 2,598 | 13,252 | 19,808 | 0 | 15 | - | - |
Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises | ||||||||||
-780 | 0 | 0 | - | - | - | - | - | - | - | - |
Acquisition of non-controlling interest | ||||||||||
2,960 | 0 | 0 | - | - | - | - | - | - | - | - |
Repayment of line of credit | ||||||||||
- | - | - | - | - | - | - | - | - | 12,175 | 160 |
Net cash provided by financing activities | ||||||||||
105,397 | 31,037 | 95,690 | 7,786 | 84,351 | 72,461 | 52,691 | 5,325 | 28,010 | -9,693 | 28,604 |
Increase (Decrease) in cash and cash equivalents | ||||||||||
-1,497 | -92 | 4,650 | - | - | - | - | - | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | ||||||||||
- | - | - | - | - | -1 | 0 | 1 | -3 | -102 | 210 |
Increase (decrease) in cash and cash equivalents | ||||||||||
- | - | - | -38,496 | 17,088 | 6,824 | 28,073 | -11,704 | -2,648 | -10,297 | 16,180 |
Supplemental disclosure: | ||||||||||
Amounts accrued for purchases of property and equipment | ||||||||||
0 | 559 | 1,254 | 164 | 225 | 12 | 139 | - | - | - | - |
Supplemental disclosures: | ||||||||||
Common stock issued for purchase of Bioject | ||||||||||
- | - | - | 4,300 | 0 | 0 | - | - | - | - | - |
Interest paid | ||||||||||
2,717 | 0 | 0 | - | - | - | - | - | - | - | - |
Equity component of issuance of convertible notes | ||||||||||
15,752 | 0 | 0 | - | - | - | - | - | - | - | - |
Right-of-use assets obtained in exchange for lease obligations | ||||||||||
14,634 | - | - | - | - | - | - | - | - | - | - |